{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:32:05Z","timestamp":1789205525454,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,4,9]],"date-time":"2012-04-09T00:00:00Z","timestamp":1333929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Variant Creutzfeldt\u2010Jakob disease (vCJD) is a rare, progressive fatal noninflammatory neurodegenerative disease. Ireland has the second highest rate of vCJD in the world with an ongoing risk of vCJD transmission through blood transfusion. Prion\u2010removing filters have been developed to reduce the risk of vCJD transmission. This study aimed to evaluate the cost\u2010effectiveness of implementing a policy of prion filtration of red blood cells (RBCs) in the Republic of Ireland.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> A cost\u2010effectiveness model was developed to simulate the likelihood of RBC recipients developing clinical vCJD as a result of being transfused with infected RBCs. Model variables were collected from published literature and expert opinion. Costs were estimated based on the processing changes required to implement prion filtration.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> In the absence of prion filtration, it is estimated that two individuals will develop clinical vCJD arising from RBC transfusions over a 10\u2010year time horizon. The discounted life\u2010years lost will be 18.5 years. With prion filtration, there will be no deaths or life\u2010years lost. The discounted cost of universal prion filtration is \u20ac68.2 million over 10 years with a corresponding incremental cost\u2010effectiveness ratio of \u20ac3.7 million per life\u2010year gained. In 25.3% of simulations there were no deaths from vCJD infection through infected blood transfusions, irrespective of prion filtration.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Prion filtration is considered not cost\u2010effective by traditional measures. Although numerous non\u2013cost\u2010effective blood safety strategies have been implemented in the past, consideration should be given to the most efficient use of finite resources in transfusion medicine.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03637.x","type":"journal-article","created":{"date-parts":[[2012,4,9]],"date-time":"2012-04-09T10:41:54Z","timestamp":1333968114000},"page":"2285-2293","source":"Crossref","is-referenced-by-count":16,"title":["Cost\u2010effectiveness of prion filtration of red blood cells to reduce the risk of transfusion\u2010transmitted variant Creutzfeldt\u2010Jakob disease in the Republic of Ireland"],"prefix":"10.1111","volume":"52","author":[{"given":"Conor","family":"Teljeur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Flattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ir\u00edn","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,9]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"US Department of Health and Human Services Centers for Disease Control and Prevention.Chronic wasting disease [Internet]. CDC;2011. [cited 2011 Jan 21]. Available from: URL:http:\/\/www.cdc.gov\/ncidod\/dvrd\/cwd\/"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1880"},{"key":"e_1_2_8_5_2","unstructured":"European Creutzfeldt Jakob Disease Surveillance Network.Current data (August 2011) [Internet]. EUROCJD;2011. [cited 2011 Aug 31]. Available from: URL:http:\/\/www.eurocjd.ed.ac.uk"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2010.09.003"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00918.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00078-11"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62308-2"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69897-8"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03133.x"},{"key":"e_1_2_8_12_2","volume-title":"Guidelines for the economic evaluation of health technologies in Ireland","author":"Health Information and Quality Authority","year":"2010"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00933.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2004.0017"},{"key":"e_1_2_8_16_2","volume-title":"Annual report 2009","author":"Irish Blood Transfusion Service","year":"2010"},{"key":"e_1_2_8_17_2","unstructured":"Spongiform Encephalopathy Advisory Committee (SEAC) (UK).SEAC position statement on TSE infectivity in blood [Internet]. SEAC Website;2008. [cited 2010 Apr 26]. Available from: URL:http:\/\/webarchive.nationalarchives.gov.uk\/20110316162913\/http:\/\/www.seac.gov.uk\/statements\/statement0806.htm"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16812-8"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02500.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2007.09.003"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01342-2"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-3-4"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07376.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-26"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015626"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00865.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182099004138"},{"key":"e_1_2_8_28_2","unstructured":"R Development Core Team.R: a language and environment for statistical computing [Internet]. Vienna.2010. [cited 2010 Oct 5]. Available from: URL:http:\/\/www.R\u2010project.org"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01968.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00392.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030021"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00379.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00280.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00198.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-3-28"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03199.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03637.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T16:39:38Z","timestamp":1697301578000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03637.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,9]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03637.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03637.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,9]]}}}